Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: January 24, 2003
Last updated: December 17, 2013
Last verified: May 2007